Federated Hermes, Inc. Pacira Bio Sciences, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 177 shares of PCRX stock, worth $3,446. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177

Previous 86,408 99.8%

Holding current value

$3,446

Previous $2.47 Million 99.92%

% of portfolio

0.0%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$11.7 - $28.46 $1.01 Million - $2.45 Million	-86,231 Reduced 99.8%	177 $2,000
Q2 2024 Aug 08, 2024	SELL	$25.5 - $31.51 $230,647 - $285,007	-9,045 Reduced 9.48%	86,408 $2.47 Million
Q1 2024 May 14, 2024	SELL	$27.7 - $35.48 $7.79 Million - $9.98 Million	-281,204 Reduced 74.66%	95,453 $2.79 Million
Q4 2023 Jan 31, 2024	SELL	$26.32 - $34.31 $310,839 - $405,201	-11,810 Reduced 3.04%	376,657 $12.7 Million
Q3 2023 Nov 13, 2023	SELL	$30.68 - $40.09 $601,051 - $785,403	-19,591 Reduced 4.8%	388,467 $11.9 Million
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $9.33 Million - $12.3 Million	258,394 Added 172.65%	408,058 $16.4 Million
Q1 2023 May 08, 2023	BUY	$35.53 - $43.38 $5.32 Million - $6.49 Million	149,619 Added 332486.66%	149,664 $6.11 Million
Q4 2022 Feb 13, 2023	SELL	$38.19 - $57.45 $5,690 - $8,560	-149 Reduced 76.8%	45 $1,000
Q3 2022 Nov 14, 2022	SELL	$51.24 - $58.89 $10,504 - $12,072	-205 Reduced 51.38%	194 $10,000
Q2 2022 Aug 15, 2022	SELL	$51.49 - $81.64 $4.15 Million - $6.58 Million	-80,543 Reduced 99.51%	399 $23,000
Q1 2022 May 13, 2022	SELL	$60.03 - $76.49 $18,129 - $23,099	-302 Reduced 0.37%	80,942 $6.18 Million
Q4 2021 Feb 14, 2022	BUY	$47.97 - $62.21 $916,802 - $1.19 Million	19,112 Added 30.76%	81,244 $4.89 Million
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $3.05 Million - $3.43 Million	-55,888 Reduced 47.35%	62,132 $3.48 Million
Q2 2021 Aug 16, 2021	SELL	$59.18 - $69.99 $1.18 Million - $1.4 Million	-19,998 Reduced 14.49%	118,020 $7.16 Million
Q1 2021 May 13, 2021	SELL	$59.31 - $78.82 $2.65 Million - $3.52 Million	-44,662 Reduced 24.45%	138,018 $9.67 Million
Q4 2020 Feb 12, 2021	BUY	$50.47 - $66.26 $215,759 - $283,261	4,275 Added 2.4%	182,680 $10.9 Million
Q3 2020 Nov 12, 2020	BUY	$51.97 - $63.0 $3.87 Million - $4.69 Million	74,396 Added 71.53%	178,405 $10.7 Million
Q2 2020 Aug 13, 2020	BUY	$30.8 - $52.47 $2.64 Million - $4.5 Million	85,673 Added 467.24%	104,009 $5.46 Million
Q1 2020 May 13, 2020	BUY	$28.4 - $50.7 $455,394 - $812,974	16,035 Added 696.87%	18,336 $615,000
Q4 2019 Feb 14, 2020	SELL	$36.31 - $46.83 $4.18 Million - $5.4 Million	-115,249 Reduced 98.04%	2,301 $104,000
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $4.01 Million - $5.06 Million	-112,460 Reduced 48.89%	117,550 $4.48 Million
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $810,866 - $1.06 Million	22,173 Added 10.67%	230,010 $10 Million
Q1 2019 May 10, 2019	SELL	$36.47 - $42.17 $2.05 Million - $2.37 Million	-56,132 Reduced 21.26%	207,837 $7.91 Million
Q4 2018 Feb 13, 2019	BUY	$41.31 - $52.16 $3.28 Million - $4.14 Million	79,415 Added 43.03%	263,969 $11.4 Million
Q3 2018 Nov 13, 2018	BUY	$32.85 - $52.0 $6.06 Million - $9.6 Million	184,554 New	184,554 $9.07 Million

Others Institutions Holding PCRX

# of Institutions

263

Shares Held

50.4M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Pacira Bio Sciences, Inc. Transaction History